Glutamate and glutamine: A review of in vivo MRS in the human brain

NMR in Biomedicine

Volumn 26, Issue 12, 2013, Pages 1630-1646

  Ramadan, Saadallah ^a   Lin, Alexander ^b   Stanwell, Peter ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

13C; Glutamate; Glutamine; Human; in vivo; MRS; One dimensional; Two dimensional

Indexed keywords

13C; GLUTAMATE; GLUTAMINE; HUMAN; IN-VIVO; MRS;

BRAIN; DISEASES; MAMMALS; ONE DIMENSIONAL; TWO DIMENSIONAL;

AMINO ACIDS;

ACETIC ACID; CARBON 13; GLUTAMIC ACID; GLUTAMINE; TRACER;

ALZHEIMER DISEASE; BRAIN; BRAIN DISEASE; BRAIN REGION; HUMAN; IN VIVO STUDY; MENTAL DISEASE; NERVE DEGENERATION; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SPECTROSCOPY;

MAMMALIA;

13C; GLUTAMATE; GLUTAMINE; HUMAN; IN VIVO; MRS; ONE DIMENSIONAL; TWO DIMENSIONAL;

ANIMALS; BRAIN; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84888043365     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3045     Document Type: Review

References (146)

1. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13: 129-153.
2. 13C]glucose. J. Neurochem. 1994; 63: 1377-1385.
3. Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 1995; 15: 12-25.
4. Schousboe A. Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem. Res. 2003; 28: 347-352.
5. Schousboe A, Waagepetersen H. Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox. Res. 2005; 8: 221-225.
6. Hertz L, Zielke HR. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 2004; 27: 735-743.
7. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006; 98: 641-653.
8. 13C] NMR spectroscopy in vivo. A practical guide. NMR Biomed. 2011; 24: 958-972.
9. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 316-321.
10. Pellerin L, Magistretti P. Glutamate uptake into astrocytes stimulates aerobic glycolysis a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 10625-10629.
11. Daikhin Y, Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J. Nutr. 2000; 130: 1026S-1031S.
12. Novotny EJ, Fulbright RK, Pearl PL, Gibson KM, Rothman DL. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann. Neurol. 2003; 54: S25-S31.
13. Petroff OAC. GABA and glutamate in the human brain. Neuroscientist 2002; 8: 562-573.
14. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW, Pin JP. Metabotropic receptors for glutamate and GABA in pain. Brain Res. Rev. 2009; 60: 43-56.
15. Mason GF, Krystal JH. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR Biomed. 2006; 19: 690-701.
16. Yudkoff M, Daikhin Y, Melo TM, Nissim I, Sonnewald U, Nissim I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu. Rev. Nutr. 2007; 27: 415-430.
17. Scott CJM, Szilagyi GM, Chavez S, Ganda A, Black SE. Applications of chemical shift imaging for AD. Curr. Med. Imaging Rev. 2011; 7: 88-95.
18. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, Cohen BM, Pope HG, Renshaw PF, Ongur D. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010; 35: 834-846.
19. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 2010; 68: 785-794.
20. Sailasuta N, Ernst T, Chang L. Regional variations and the effects of age and gender on glutamate concentrations in the human brain. Magn. Reson. Imaging 2008; 26: 667-675.
21. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 1998; 39: 53-60.
22. Novotny E, Ashwal S, Shevell M. Proton magnetic resonance spectroscopy: an emerging technology in pediatric neurology research. Pediatr. Res. 1998; 44: 1-10.
23. 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol. Aging 2009; 30: 353-363.
24. 1H magnetic resonance spectroscopy findings in major depressive disorder a meta-analysis. Psychiatry Res. Neuroimaging 2006; 147: 1-25.
25. Petroff OAC, Errante LD, Rothman DL, Kim JH, Spencer DD. Glutamate-glutamine cycling in the epileptic human hippocampus. Epilepsia 2002; 43: 703-710.
26. Cavus I, Kasoff WS, Cassaday MP, Jacob R, Gueorguieva R, Sherwin RS, Krystal JH, Spencer DD, Abi-Saab WM. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann. Neurol. 2005; 57: 226-235.
27. 1H spectroscopic imaging at 4.1 Tesla. J. Child Neurol. 1999; 14: 524-528.
28. Köstler H. Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab. Brain Dis. 1998; 13: 291-301.
29. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab. Brain Dis. 2002; 17: 415-429.
30. Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. Am. J. Neuroradiol. 2008; 29: 1612-1621.
31. Hazany S, Hesselink JR, Healy J, Imbesi S. Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 2007; 49: 121-127.
32. Horska A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin. N. Am. 2010; 20: 293-310.
33. Tate AR, Underwood J, Acosta DM, Julia-Sape M, Majos C, Moreno-Torres A, Howe FA, van der Graaf M, Lefournier V, Murphy MM, Loosemore A, Ladroue C, Wesseling P, Bosson JL, Cabanas ME, Simonetti AW, Gajewicz W, Calvar J, Capdevila A, Wilkins PR, Bell BA, Remy C, Heerschap A, Watson D, Griffiths JR, Arus C. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed. 2006; 19: 411-434.
34. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. Am. J. Neuroradiol. 2007; 28: 272-277.
35. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict. Behav. 2004; 29: 1325-1339.
36. Licata SC, Renshaw PF. Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann. NY Acad. Sci. 2010; 1187: 148-171.
37. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2004; 10: 40-68.
38. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 2003; 160: 2231-2233.
39. Shutter L, Tong KA, Holshouser BA. Proton MRS in acute traumatic brain injury: role for glutamate/glutamine and choline for outcome prediction. J. Neurotrauma 2004; 21: 1693-1705.
40. Ashwal S, Holshouser B, Tong K, Serna T, Osterdock R, Gross M, Kido D. Proton MR spectroscopy detected glutamate/glutamine is increased in children with traumatic brain injury. J. Neurotrauma 2004; 21: 1539-1552.
41. 13C magnetic resonance spectroscopy study. Magn. Reson. Mater. Phys. Biol. Med. 2003; 16: 29-42.
42. Martin WRW. MR spectroscopy in neurodegenerative disease. Mol. Imaging Biol. 2007; 9: 196-203.
43. 1H magnetic resonance spectroscopy. Magn. Reson. Med. 2002; 48: 949-958.
44. Kreis R, Pfenninger J, Herschkowitz N, Boesch C. In vivo proton magnetic resonance spectroscopy in a case of Reye's syndrome. Intens. Care Med. 1995; 21: 266-269.
45. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J. Inherit. Metab. Dis. 2007; 30: 865-879.
46. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992; 182: 19-27.
47. 1H MR spectroscopy and neuropsychologic status of patients with hepatic encephalopathy. Am. J. Roentgenol. 1998; 171: 1123-1130.
48. Ross BD, Jacobson S, Villamil F, Korula J, Kreis R, Ernst T, Shonk T, Moats RA. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994; 193: 457-463.
49. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2: 197-214.
50. 1H MR spectroscopic imaging. NMR Biomed. 2003; 16: 12-18.
51. Chawla S, Oleaga L, Wang S, Krejza J, Wolf RL, Woo JH, O'Rourke DM, Judy KD, Grady MS, Melhem ER, Poptani H. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J. Neuroimaging 2010; 20: 3-8.
52. Chawla S, Wang S, Wolf RL, Woo JH, Wang J, O'Rourke DM, Judy KD, Grady MS, Melhem ER, Poptani H. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. Am. J. Neuroradiol. 2007; 28: 1683-1689.
53. Majos C, Julia-Sape M, Alonso J, Serrallonga M, Aguilera C, Acebes JJ, Arus C, Gili J. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. Am. J. Neuroradiol. 2004; 25: 1696-1704.
54. Pan JW, Williamson A, Cavus I, Hetherington HP, Zaveri H, Petroff OAC, Spencer DD. Neurometabolism in human epilepsy. Epilepsia 2008; 49: 31-41.
55. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
56. Zhou YX, Kierans A, Kenul D, Ge YL, Rath J, Reaume J, Grossman RI, Lui YW. Mild traumatic brain injury: longitudinal regional brain volume changes. Radiology 2013; 267: 880-890.
57. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, Petersen KF. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 2009; 30: 211-221.
58. Prost RW, Mark L, Mewissen M, Li SJ. Detection of glutamate/glutamine resonances by H-1 magnetic resonance spectroscopy at 0.5 Tesla. Magn. Reson. Med. 1997; 37: 615-618.
59. 1H MRS of breast lesions. Magn. Reson. Med. 2002; 48: 215-222.
60. Dreher W, Leibfritz D. On the use of 2-dimensional-J NMR measurements for in-vivo proton MRS - measurement of homonuclear decoupled spectra without the need for short echo times. Magn. Reson. Med. 1995; 34: 331-337.
61. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn. Reson. Med. 2004; 51: 435-440.
62. Smith SA, Levante TO, Meier BH, Ernst RR. Computer-simulations in magnetic-resonance - an object-oriented programming approach. J. Magn. Reson. A 1994; 106: 75-105.
63. Srinivasan R, Cunningham C, Chen A, Vigneron D, Hurd R, Nelson S, Pelletier D. TE-averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T. Neuroimage 2006; 30: 1171-1178.
64. Perry TL, Berry K, Hansen S, Diamond S, Mok C. Regional distribution of amino acids in human brain obtained at autopsy. Neurchemistry. 1971; 18: 513-519.
65. Lavoie J, Giguere JF, Layrargues GP, Butterworth RF. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J. Neurochem. 1987; 49: 692-697.
66. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004; 21: 1762-1771.
67. Jang DP, Lee JM, Lee E, Park S, Kim JJ, Namkoong K, Yoon KJ, Kim IY, Kim SI. Interindividual reproducibility of glutamate quantification using 1.5-T proton magnetic resonance spectroscopy. Magn. Reson. Med. 2005; 53: 708-712.
68. 1H spectra with LCModel. NMR Biomed. 2001; 14: 260-264.
69. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn. Reson. Med. 2008; 60: 964-969.
70. Yang SL, Hu JN, Kou ZF, Yang YH. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4 T. Magn. Reson. Med. 2008; 59: 236-244.
71. Forsen S, Hoffman RA. Study of moderately rapid chemical exchange reactions by means of nuclear magnetic double resonance. J. Chem. Phys. 1963; 39: 2892-2901.
72. Cai K, Haris M, Singh A, Kogan F, Greenberg JH, Hariharan H, Detre JA, Reddy R. Magnetic resonance imaging of glutamate. Nature Med. 2012; 18: 302-306.
73. Zhou J, van Zijl PCM. Chemical exchange saturation transfer imaging and spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2006; 48: 109-136.
74. 1H magnetic resonance spectroscopy. J. Magn. Reson. Imaging 2011; 34: 645-652.
75. Ramadan S. Phase-rotation in in-vivo localised spectroscopy. Concepts Magn. Reson. 2007; 30: 147-153.
76. Hennig J. The application of phase rotation for localized in vivo proton spectroscopy with short echo times. J. Magn. Reson. 1992; 96: 40-49.
77. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn. Reson. Med. 2009; 61: 1279-1285.
78. Ordidge RJ, Connelly A, Lohman JAB. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 1986; 66: 283-294.
79. Kirov II, Tal A, Babb JS, Lui YW, Grossman RI, Gonen O. Diffuse axonal injury in mild traumatic brain injury a 3D multivoxel proton MR spectroscopy study. J. Neurol. 2013; 260: 242-252.
80. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001; 153: 155-177.
81. Kassem MNE, Bartha R. Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction. Magn. Reson. Med. 2003; 49: 918-927.
82. 1H NMR spectrosocopy of human brain at very high magnetic fields. Appl. Magn. Reson. 2005; 29: 139-157.
83. 1H NMR spectroscopy of the human brain at 7 T. Magn. Reson. Med. 2001; 46: 451-456.
84. Mangia S, Tkac I, Gruetter R, Van de Moortele PF, Maraviglia B, Ugurbil K. Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from H-1 NMR spectroscopy in the human visual cortex. J. Cereb. Blood Flow Metab. 2007; 27: 1055-1063.
85. Schaller B, Mekle R, Xin LJ, Kunz N, Gruetter R. Net increase of lactate and glutamate concentration in activated human visual cortex detected with magnetic resonance spectroscopy at 7 Tesla. J. Neurosci. Res. 2013; 91: 1076-1083.
86. 1 shimming. NMR Biomed. 2012; 25: 152-160.
87. Henning A, Fuchs A, Murdoch JB, Boesiger P. Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for H-1-MRSI of the human brain at 7 T with minimal signal loss. NMR Biomed. 2009; 22: 683-696.
88. Rothman DL, Behar KL, Hetherington HP, Shulman RG. Homonuclear H-1 double-resonance difference spectroscopy of the rat brain in vivo. Proc. Natl Acad. Sci. USA Biol. Sci. 1984; 81: 6330-6334.
89. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998; 11: 266-272.
90. Waddell KW, Zanjanipour P, Pradhan S, Xu L, Welch EB, Joers JM, Martin PR, Avison MJ, Gore JC. Anterior cingulate and cerebellar GABA and Glu correlations measured by (1)H J-difference spectroscopy. Magn. Reson. Imaging 2011; 29: 19-24.
91. Lee HK, Yaman A, Nalcioglu O. Homonuclear J-refocused spectral editing technique for quantification of glutamine and glutamate by H-1-NMR spectroscopy. Magn. Reson. Med. 1995; 34: 253-259.
92. Snyder J, Thompson RB, Wilman AH. Difference spectroscopy using PRESS asymmetry: application to glutamate, glutamine, and myo-inositol. NMR Biomed. 2010; 23: 41-47.
93. Gambarota G, van der Graaf M, Klomp D, Mulkern RV, Heerschap A. Echo-time independent signal modulations using PRESS sequences a new approach to spectral editing of strongly coupled AB spin systems. J. Magn. Reson. 2005; 177: 299-306.
94. Snyder J, Wilman A. Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7 T. J. Magn. Reson. 2010; 203: 66-72.
95. Hennig J, Thiel T, Speck O. Improved sensitivity to overlapping multiplet signals in in vivo proton spectroscopy using a multiecho volume selective (CPRESS) experiment. Magn. Reson. Med. 1997; 37: 816-820.
96. Mayer D, Spielman DM. Detection of glutamate in the human brain at 3 Tesla using optimized CT-PRESS. In Proceedings of the 10th Scientific Meeting ISMRM, Honolulu, Hawai'i, USA, 2002; 785.
97. Hancu I. Optimized glutamate detection at 3T. J. Magn. Reson. Imaging 2009; 30: 1155-1162.
98. Choi C, Coupland NJ, Bhardwaj PP, Malykhin N, Gheorghiu D, Allen PS. Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 Tesla. Magn. Reson. Med. 2006; 55: 997-1005.
99. Posse S, Tedeschi G, Risinger R, Ogg R, Lebihan D. High-speed H-1 spectroscopic imaging in human brain by echo-planar spatial-spectral encoding. Magn. Reson. Med. 1995; 33: 34-40.
100. Posse S, Otazo R, Caprihan A, Bustillo J, Chen HJ, Henry PG, Marjanska M, Gasparovic C, Zuo C, Magnotta V, Mueller B, Mullins P, Renshaw P, Ugurbil K, Lim KO, Alger JR. Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla. Magn. Reson. Med. 2007; 58: 236-244.
101. Otazo R, Tsai SY, Lin FH, Posse S. Accelerated short-TE 3D proton echo-planar spectroscopic imaging using 2D-SENSE with a 32-channel array coil. Magn. Reson. Med. 2007; 58: 1107-1116.
102. Lin FH, Tsai SY, Otazo R, Caprihan A, Wald LL, Belliveau JW, Posse S. Sensitivity-encoded (SENSE) proton echo-planar spectroscopic imaging (PEPSI) in the human brain. Magn. Reson. Med. 2007; 57: 249-257.
103. Tsai SY, Otazo R, Posse S, Lin YR, Chung HW, Wald LL, Wiggins GC, Lin FH. Accelerated proton echo planar spectroscopic imaging (PEPSI) using GRAPPA with a 32-channel phased-array coil. Magn. Reson. Med. 2008; 59: 989-998.
104. Thompson RB, Allen PS. A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: its application to glutamate. Magn. Reson. Med. 1998; 39: 762-771.
105. Pan JW, Mason GF, Pohost GM, Hetherington HP. Spectroscopic imaging of human brain glutamate by water-suppressed J-refocused coherence transfer at 4.1 T. Magn. Reson. Med. 1996; 36: 7-12.
106. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30: 672-679.
107. Gussew A, Rzanny R, Erdtel M, Scholle HC, Kaiser WA, Mentzel HJ, Reichenbach JR. Time-resolved functional H-1 MR spectroscopic detection of glutamate concentration changes in the brain during acute heat pain stimulation. Neuroimage 2010; 49: 1895-1902.
108. Wijnen JR, van Asten JJA, Klomp DWJ, Sjobakk TE, Gribbestad IS, Scheenen TWJ, Heerschap A. Short echo time H-1 MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses; reproducibility and variance in a dual center setting. J. Magn. Reson. Imaging 2010; 31: 61-70.
109. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magn. Reson. Mater. Phys. Biol. Med. 2001; 12: 141-152.
110. Aue WP, Bartholdi E, Ernst RR. Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J. Chem. Phys. 1976; 64: 2229-2246.
111. Aue WP, Karhan J, Ernst RR. Homonuclear broad-band decoupling and 2-dimensional J-resolved NMR-spectroscopy. J. Chem. Phys. 1976; 64: 4226-4227.
112. Schulte RF, Boesiger P. ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. NMR Biomed. 2006; 19: 255-263.
113. Thomas MA, Yue K, Binesh N, Davanzo P, Kumar A, Siegel B, Frye M, Curran J, Lufkin R, Martin P, Guze B. Localized two-dimensional shift correlated MR spectroscopy of human brain. Magn. Reson. Med. 2001; 46: 58-67.
114. Thomas MA, Hattori N, Umeda M, Sawada T, Naruse S. Evaluation of two-dimensional L-COSY and JPRESS using a 3T MRI scanner: from phantoms to human brain in vivo. NMR Biomed. 2003; 16: 245-251.
115. Frias-Martinez E, Rajakumar N, Liu X, Singhal A, Banakar S, Lipnick S, Verma G, Ramadan S, Kumar A, Thomas MA. ProFit-based quantitation of cerebral metabolites using 2D L-COSY at 3T. In Proceedings of the 16th Scientific Meeting ISMRM, Toronto, Ontario, Canada, 2008; 691.
116. Ramadan S, Mountford C. Adiabatic localized correlation spectroscopy (AL-COSY) - application in muscle and brain. J. Magn. Reson. Imaging 2011; 33: 1447-1455.
117. Andronesi OC, Ramadan S, Mountford CE, Sorensen AG. Low-power adiabatic sequences for in vivo localized two-dimensional chemical shift correlated MR spectroscopy. Magn. Reson. Med. 2010; 64: 1542-1556.
118. Watanabe H, Takaya N, Mitsumori F. Simultaneous observation of glutamate, γ-aminobutyric acid, and glutamine in human brain at 4.7 T using localized two-dimensional constant-time correlation spectroscopy. NMR Biomed. 2008; 21: 518-526.
119. Jensen JE, Licata SC, Ongur D, Friedman SD, Prescot AP, Henry ME, Renshaw PF. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009; 22: 762-769.
120. Chong DGQ, Kreis R, Bolliger CS, Boesch C, Slotboom J. Two-dimensional linear-combination model fitting of magnetic resonance spectra to define the macromolecule baseline using FiTAID a fitting tool for arrays of interrelated datasets. Magn. Reson. Mater. Phys. Biol. Med. 2011; 24: 147-164.
121. Gonenc A, Govind V, Sheriff S, Maudsley AA. Comparison of spectral fitting methods for overlapping J-coupled metabolite resonances. Magn. Reson. Med. 2010; 64: 623-628.
122. Gu M, Zahr NM, Spielman DM, Sullivan EV, Pfefferbaum A, Mayer D. Quantification of glutamate and glutamine using constant-time point-resolved spectroscopy at 3 T. NMR Biomed. 2013; 26: 164-172.
123. Giraudeau P, Massou S, Robin Y, Cahoreau E, Portais JC, Akoka S. Ultrafast quantitative 2D NMR: an efficient tool for the measurement of specific isotopic enrichments in complex biological mixtures. Anal. Chem. 2011; 83: 3112-3119.
124. Bluml S, Hwang JH, Moreno A, Ross BD. Novel peak assignments of in vivo (13)C MRS in human brain at 1.5 T. J. Magn. Reson. 2000; 143: 292-298.
125. Bluml S, Moreno-Torres A, Shic F, Nguy CH, Ross BD. Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed. 2002; 15: 1-5.
126. 13C MR spectra acquired from human brain in vivo. J. Magn. Reson. 2003; 162: 259-268.
127. 13C MRS examinations of the brain. Magn. Reson. Med. 2001; 46: 39-48.
128. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011; 24: 943-957.
129. de Graaf RA. In Vivo NMR Spectroscopy: Principles and Techniques. Wiley: Chichester, 2007; 118-119.
130. Shaka AJ, Keeler J, Frenkiel T, Freeman R. An improved sequence for broadband decoupling: WALTZ-16. J. Magn. Reson. 1983; 52: 335-338.
131. Ross B, Lin A, Harris K, Bhattacharya P, Schweinsburg B. Clinical experience with C-13 MRS in vivo. NMR Biomed. 2003; 16: 358-369.
132. 13C MRS brain exam for clinical diagnostic use. J. Magn. Reson. 2010; 207: 352-355.
133. 13C MRS of the human brain at 4 Tesla. Magn. Reson. Med. 1996; 36: 659-664.
134. 13C NMR. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 8235-8240.
135. Gruetter R, Seaquist ER, Kim S, Ugurbil K. Localized in vivo C-13-NMR of glutamate metabolism in the human brain: initial results at 4 Tesla. Dev. Neurosci. 1998; 20: 380-388.
136. 1H spectra. Magn. Reson. Imaging 2008; 26: 413-419.
137. Choi IY, Tkac I, Gruetter R. Single-shot, three-dimensional 'non-echo' localization method for in vivo NMR spectroscopy. Magn. Reson. Med. 2000; 44: 387-394.
138. Allouche-Arnon H, Wade T, Waldner LF, Miller VN, Gomori JM, Katz-Brull R, McKenzie CA. In vivo magnetic resonance imaging of glucose - initial experience. Contrast Media Mol. Imaging 2013; 8: 72-82.
139. 13C diethyl succinate. J. Am. Chem. Soc. 2012; 134: 934-943.
140. 13C-succinate imaging of brain cancer. J. Magn. Reson. 2007; 186: 150-155.
141. 2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc. Natl. Acad. Sci. U. S. A. 2009; 106: 19801-19806.
142. 13C]glutamate. Magn. Reson. Med. 2011; 66: 18-23.
143. 13C]glucose MRS in chronic hepatic encephalopathy in man. Magn. Reson. Med. 2001; 45: 981-993.
144. 13C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders. NMR Biomed. 2001; 14: 19-32.
145. Sailasuta N, Abulseoud O, Harris KC, Ross BD. Glial dysfunction in abstinent methamphetamine abusers. J. Cereb. Blood Flow Metab. 2010; 30: 950-960.
146. Frias-Martinez E, Rajakumar N, Ramadan S, Banakar S, Liu X, Singhal A, Thomas MA. A pilot comparison of 2D and 1D MR spectroscopic quantitation of metabolites in healthy human brain at 3T. In Proceedings of the 16th Scientific Meeting ISMRM, Toronto, Ontario, Canada, 2008; 1603.